5 days ago · Vertex is also evaluating suzetrigine in peripheral neuropathic pain (PNP). The company’s Phase 3 pivotal program for suzetrigine in patients with painful diabetic peripheral …

The U.S. Food and Drug Administration approved twice-daily Journavx for the treatment of adults with moderate-to-severe acute pain. Vertex has established a wholesale acquisition cost for …

5 days ago · According to a new announcement, the FDA has approved suzetrigine (Vertex Pharmaceuticals), an oral selective NaV1.8 pain signal inhibitor, to treat patients who …

3 days ago · With suzetrigine, developed by pharmaceutical company Vertex, they finally succeeded. The FDA’s approval is based on two phase 3 clinical trials conducted in patients …

Jul 30, 2024 · Suzetrigine (formerly VX-548) is an investigational oral, selective NaV1.8 pain signal inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a …

Dec 19, 2024 · Suzetrigine is an investigational medicine for acute and peripheral neuropathic pain, including lumbosacral radiculopathy. N=218 patients*, randomized 1:1 suzetrigine vs. …

Aug 20, 2024 · In January 2024 Vertex announced promising results of clinical trials of VX-548, which it is calling suzetrigine, showing that it dampened acute pain levels by about one half on …

Oct 18, 2024 · Vertex recently initiated a Phase 3 pivotal program of suzetrigine in patients with painful diabetic peripheral neuropathy (DPN) and has completed enrollment in its Phase 2 …

It was developed by Vertex Pharmaceuticals, [5] and was approved for medical use in the United States in January 2025. [2][6] Suzetrigine is the first medication to be approved by the US …

4 days ago · New drug suzetrigine, known by its brand name Journavx, has been approved to treat moderate to severe pain. ... Vertex estimates nearly 10% of acute pain patients treated …